Skip to main content
. 2020 May 18;11(15):4581–4588. doi: 10.7150/jca.44766

Table 4.

Multivariate analysis of EFS and OS in chemotherapy-only group and allo-HSCT group.

Variables EFS OS
HR(95%CI) P-value HR(95%CI) P-value
Chemotherapy-only group
SPNS2 3.072 (1.378-6.851) 0.006 1.884 (1.006-3.526) 0.048
SPNS3 1.525 (0.737-3.156) 0.225 1.287 (0.728-2.276) 0.386
PB (≥20 vs. <20 × 10%) 0.680 (0.341-1.359) 0.275 0.653 (0.374-1.140) 0.134
FLT3-ITD (positive vs. negative) 0.889 (0.398-1.988) 0.775 0.863 (0.443-1.681) 0.666
NPM1 (mutated vs. wild) 0.870 (0.398-1.948) 0.736 0.875 (0.473-1.617) 0.670
DNMT3A (mutated vs. wild) 1.265 (0.595-2.687) 0.541 1.626 (0.920-2.871) 0.094
TET2 (mutated vs. wild) 0.476 (0.161-1.410) 0.180 0.619 (0.296-1.294) 0.202
Allo-HSCT
SPNS3 1.092 (0.289-4.126) 0.897 2.789 (1.257-5.339) 0.002
Age (≥60 vs. <60 years) 0.740 (0.235-2.331) 0.607 1.061 (0.560-2.010) 0.856
PB (≥20 vs. <20 × 10%) 0.428 (0.149-1.227) 0.114 0.774 (0.404-1.481) 0.439
FLT3-ITD (positive vs. negative) 2.068 (0.450-9.508) 0.351 2.359 (1.062-5.240) 0.035
NPM1 (mutated vs. wild) 0.597 (0.132-2.697) 0.502 0.502 (0.214-1.174) 0.112
IDH1/IDH2 (mutated vs. wild) 1.456 (0.407-5.204) 0.563 0.789 (0.364-1.707) 0.547
RUNX1(mutated vs. wild) 2.275 (0.415-12.468) 0.344 1.529 (0.614-3.807) 0.361

EFS event-free survival, OS overall survival, HR hazard ratio, CI confidential interval, PB peripheral blood